User:Mr. Ibrahem/Oritavancin

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Oritavancin
Clinical data
Pronunciation/oʊˌrɪtəˈvænsɪn/
oh-RIT-ə-VAN-sin
Trade namesOrbactiv, Kimyrsa, Tenkasi, others
Other namesLY333328
AHFS/Drugs.comMonograph
MedlinePlusa614042
License data
Routes of
administration		Intravenous
Drug classAntibiotic (lipoglycopeptide)[1]
Legal status
Legal status
Identifiers
  • (4R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-α-L-arabinohexopyranosyl)-N3-(p-(p-chlorophenyl)benzyl)vancomycin
Chemical and physical data
FormulaC86H97Cl3N10O26
Molar mass1793.12 g·mol−1
3D model (JSmol)
  • C[C@H]1[C@@H]([C@@](C[C@@H](O1)O[C@H]2[C@H]3C(=O)N[C@H](C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)[C@H](C(=O)N3)NC(=O)[C@H]6C7=CC(=C(C(=C7)OC8=C(C=C(C=C8)[C@H]([C@H](C(=O)N[C@H](C(=O)N6)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O[C@H]1C[C@]([C@H]([C@@H](O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C2C=C1)Cl)O)C(=O)O)(C)N)O
  • InChI=1S/C86H97Cl3N10O26/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66+,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-/m0/s1 ☒N
  • Key:VHFGEBVPHAGQPI-MYYQHNLBSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Oritavancin, sold under the brand name Orbactiv among others, is an antibiotic used to treat skin and skin structure infections such as cellulitis and skin abscesses.[1][4] It is also effective against MRSA.[1] It is given by injection into a vein.[1]

Common side effects include diarrhea, nausea, dizziness, headache, itchiness, fever, and liver problems.[1] Safety in pregnancy is unclear.[5] It is a glycopeptide specifically a lipoglycopeptide and is similar to vancomycin.[1] It works by stopping bacteria from making their cell wall.[4]

Oritavancin was approved for medical use in the United States in 2014 and Europe in 2015.[1][4] In the United States a course of treatments costs about 3,000 USD.[6] It; however, is not commercially available in the United Kingdom or Europe as of 2021.[7]

References[edit]

  1. ^ a b c d e f g h i "Oritavancin Monograph for Professionals". Drugs.com. Archived from the original on 28 January 2021. Retrieved 8 November 2021.
  2. ^ "Orbactiv- oritavancin injection, powder, lyophilized, for solution". DailyMed. Archived from the original on 24 March 2021. Retrieved 18 December 2020.
  3. ^ "Kimyrsa- oritavancin diphosphate injection, powder, lyophilized, for solution". DailyMed. Archived from the original on 19 April 2021. Retrieved 31 March 2021.
  4. ^ a b c d e "Orbactiv EPAR". Archived from the original on 2020-12-28. Retrieved 2021-09-05.
  5. ^ "Oritavancin Use During Pregnancy". Drugs.com. Archived from the original on 29 November 2020. Retrieved 8 November 2021.
  6. ^ "Orbactiv Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 13 June 2016. Retrieved 8 November 2021.
  7. ^ "Oritavancin". SPS - Specialist Pharmacy Service. 28 September 2015. Archived from the original on 9 November 2021. Retrieved 8 November 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Oritavancin&oldid=1216599513"